Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
Open Access
- 9 June 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (3), 227-235
- https://doi.org/10.1016/j.clcc.2021.06.002
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise ReviewClinical Colorectal Cancer, 2016
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- TAS-102, a novel antitumor agent: A review of the mechanism of actionCancer Treatment Reviews, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerThe New England Journal of Medicine, 2015
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyThe Lancet Oncology, 2014
- Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal CancerJNCI Journal of the National Cancer Institute, 2014
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Tie2 in Tumor Endothelial Signaling and Survival: Implications for Antiangiogenic TherapyMolecular Cancer Research, 2009